Journal articleBr J Cancer2020
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
- Journal
- Br J Cancer
- Published
- 9 March 2020
- Citations
- 42
- Type
- Article
- License
- cc by
- Full text
- Open access, reuse-licensed (cc by)
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Its licensed text is not loaded here yet, so most questions will be declined.
Try